77 results about "Postoperative survival" patented technology

The invention relates to an immune gene prognosis model for predicting hepatocellular carcinoma tumor immune infiltration and postoperative survival time, and belongs to the technical field of biological medicines. The model can be used for evaluating the infiltration degree of immune cells in a tumor in clinical practice by detecting the expression levels of 22 specific immune related genes of ahepatocellular carcinoma patient, so that the model can be used for predicting hepatocellular carcinoma tumor immune infiltration in clinical practice and improve the prediction capability of the liver cancer immunotherapy response. The model can be used for judging the postoperative overall survival risk of a patient and guiding the formulation of a postoperative treatment strategy, and the corresponding microarray chip kit can realize the standardization and convenience of detection. Meanwhile, the immune gene prognosis model provided by the invention can increase the prediction accuracy andthe clinical net income of a hepatocellular carcinoma TNM staging system on the total survival time of three years and five years after operation. As a molecular marker for objectively and accuratelyevaluating the tumor immune state and poor prognosis risk of hepatocellular carcinoma, the model can realize accurate implementation of hepatocellular carcinoma immunotherapy and accurate prognosis prediction.

The invention discloses a product for performing assisted prediction on postoperative survival time length of an esophageal squamous carcinoma patient. The product comprises substances for detecting 178 miRNA expression quantity substances comprising hsa-miR-218-5p, hsa-miR-142-3p, hsa-miR-150-5p and hsa-miR-205-5p, and records a carrier with the diagnostic criteria and functional expressions as follows: if 0.94dig is less than dip, the postoperative survival time of the esophageal squamous carcinoma patient to be tested is more than 5 years, and if the 0.94dig is more than or equal to dip, the postoperative survival time of the esophageal squamous carcinoma patient to be tested is less than 5 years. After the result of the postoperative survival time of the esophageal squamous carcinoma patient is predicted by using the product, more accurate and effective treatment is adopted, and the patient condition can be effectively improved. In addition, the medicine which influences the expression quantities of hsa-miR-218-5p, hsa-miR-142-3p, hsa-miR-150-5p and hsa-miR-205-5p can be used for treating the esophageal squamous carcinoma.

The invention discloses a diagnosis kit for rectal carcinoma prognosis early warning and an application of the diagnosis kit. According to the diagnosis kit provided by the invention, the following 13immunity related genes, which are related to rectal carcinoma prognosis, are discovered through a Spearman transfer model: an AXL gene, a BCL3 gene, an ABR gene, an MAP3K1 gene, a CASP8 gene, an RPS6KA1 gene, a VASP gene, an SIRT1 gene, a BCL2L1 gene, an AKIRIN2 gene, a PIN1 gene, an MEF2A gene and a PCBP2 gene. Based upon experiments, it is verified that the 13 immunity related genes are relatedto the rectal carcinoma prognosis; and the 13 immunity related genes, as markers, are applicable to adjuvant prediction of postoperative survival time of patients with rectal carcinoma.

The invention relates to the technical field of medical molecular biology and provides a method for detecting the serum marker of pancreatic cancer. The pancreatic cancer has high grade malignancy, difficult early diagnosis and poor prognosis, and the pancreatic cancer also lacks really effective solution, with surgical resection as the only therapeutic method to prolong survival period. Unfortunately, most of pancreatic cancer patients are in the advanced stage (TNM belongs to III and IV stages) and miss the surgical option. The invention aims at providing a method for detecting the serum marker of pancreatic cancer and applying the method to early diagnosis of pancreatic cancer and clinical judgment of laparotomy indication. The study proves that in the invention, the expression level of miR-196a in the serum is closely related to the postoperative survival period of pancreatic cancer; the study later proves that the relative expression abundance of miR-196a can well distinguish resectable pancreatic cancer (TNM belongs to I and II stages) from pancreatic cancer in advanced stage (TNM belongs to III and IV stages), so the method in the invention can be used for detecting the serum marker microRNA-196a of pancreatic cancer, and the method further has the advantages of convenient detection, good sensitivity and high accuracy.

The invention provides a cervical cancer postoperative survival prediction method, system and device and a medium, and belongs to the technical field of medicine. On the basis of traditional patient evaluation, the influence of pathological factors on postoperative survival of patients is emphasized, and on the basis of a machine learning algorithm, a clinical prediction model for predicting postoperative survival of early cervical cancer patients is developed. According to the invention, more personalized clinical guidance opinions can be provided for selection and accurate treatment of earlycervical cancer postoperative adjuvant therapy schemes, so that the method has good practical application value.

The invention provides a method for maintaining the survival and/or function of vascular endothelial cells in the in vitro preservation process and used preserving fluid. The method and the preservingfluid are suitable for storing various organs. The in vitro liver can survive to exceed 24h during the preservation by the organ preserving liquid and in the mechanical filling process; the liver microcirculation structure is complete; no obvious damage exists; the choleresis function is good; the liver synthesis and metabolism functions are good; the in vitro preservation time of the liver is greatly prolonged; the postoperative survival rate of later-period liver transplantation patients is improved.

The invention discloses a kit used for aided prediction on postoperative survival time of esophageal squamous cell carcinoma (ESCC) patients. The kit comprises a substance used for detecting lncRNA 1 expression quantity, a substance used for detecting lncRNA 2 expression quantity, and a substance used for detecting lncRNA 3 expression quantity; the sequence of lncRNA 1 is represented by sequence 1 in a sequence table; the sequence of lncRNA 2 is represented by sequence 2 in the sequence table; and the sequence of lncRNA 3 is represented by sequence 3 in the sequence table. A plurality of ESCC patients are investigated; expression characteristics of lncRNA in cancer tissue and near cancer normal tissue are analyzed; it is observed that expression profile of a plurality of lncRNA in cancer tissue is obviously different from that of near cancer normal tissue; a model is established based on three lncRNA relative expression quantity; and the model can be used for aided prediction on postoperative survival time of esophageal squamous cell carcinoma patients.

The technical scheme of the invention provides a gene chip for predicting liver cancer metastasis and recurrence risk, which comprises a substrate and a probe arranged on the substrate, wherein the probe consists of 149 genes. The gene chip for predicting the liver cancer metastasis and the recurrence risk has the advantages that: due to the adoption of genome comparison research, a large sample independently proves that a prediction model can accurately predict and evaluate the metastasis potential of liver cancer patients. Therefore, postoperative survival and metastasis, and recurrence of the patient can be accurately predicted (even early liver cancer patients can be accurately predicted). The gene chip contributes to early identifying or predicting high-risk patients so as to perform intensive monitoring and effective intervention on the high-risk patients to further prolong the life of the tumor patients.

The invention provides a Lasso-based esophageal squamous cell carcinoma patient risk prediction column diagram model establishment method, which is used for evaluating the postoperative survival risk of esophageal squamous cell carcinoma patients. The method comprises the following steps: firstly, collecting clinical data of esophageal squamous cell carcinoma patients, analyzing the clinical data by utilizing single-factor Cox, Lasso and multi-factor Cox regression analysis methods to obtain important characteristic variables, and establishing probability prediction models with different characteristic dimensions; secondly, selecting a probability prediction model with better performance and establishing a postoperative risk prediction column diagram model of the esophageal squamous cell carcinoma patient; and finally, dividing the patients into a high-risk group and a low-risk group according to the postoperative risk prediction column diagram model of the esophageal squamous cell carcinoma patients, and verifying the reliability and effectiveness of model classification through a KM survival curve analysis method. According to the method, the postoperative survival risk of the esophageal squamous cell carcinoma patient can be accurately predicted, reference is better provided for treatment of the esophageal squamous cell carcinoma patient, and meanwhile the risk prediction cost is reduced.

The invention belongs to the technical field of medical image processing, and particularly provides a higher level brain glioma survival period prediction method based on a sparse representation framework and a higher level brain glioma survival period prediction system based on the sparse representation framework. Firstly the tumor area in an MRI image is segmented by using an image segmentationmethod based on a convolutional neural network; then the global features of the tumor area are extracted by using the method based on local SIFT feature sparse representation; feature selection is performed by using the model of combining sparse representation and structure preserving for reducing the feature redundancy and enhancing the survival period prediction accuracy, and a few high-stability and high-resolution features are selected to predict the survival period; and finally whether the survival period of the patient is greater than 22 months is predicted by using a multi-feature collaboration sparse representation classification method with combination of the multimodal features. The method has high survival period prediction accuracy, and the whole process is automatically completed by the computer without manual intervention so that the method can be used for postoperative survival period prediction of the clinical higher level brain glioma.

The invention provides an esophageal squamous cell carcinoma risk prediction method based on clinical phenotype and logistic regression analysis. The method is used for realizing prognosis survival risk assessment of esophageal squamous cell carcinoma patients. The method comprises the following steps: firstly, screening out characteristic indexes according to clinical detection data of the esophageal squamous cell carcinoma patients, and constructing a decision tree classifier according to the characteristic indexes; secondly, dividing the esophageal squamous cell carcinoma patients into early-stage esophageal squamous cell carcinoma patients and middle-late-stage esophageal squamous cell carcinoma patients by utilizing the decision tree classifier; then, obtaining blood index informationof the esophageal squamous cell carcinoma patient one week before the operation, and screening out blood indexes with high correlation with the survival risk of the esophageal squamous cell carcinomapatient, and constructiung a logistic regression model; inputting the classified blood indexes of the esophageal squamous cell carcinoma patient into the logistic regression model to obtain a prognosis survival risk probability value of the esophageal squamous cell carcinoma patient; and judging the prognosis survival risk. According to the method, the postoperative survival state of the esophageal squamous cell carcinoma patient can be accurately judged, the risk prediction performance is improved, and the risk prediction cost is reduced.

The invention relates to a cultivating method of hyriopsis cumingii with a golden yellow shell. The method is characterized by comprising the following steps of (1), selecting 4-6 parent hyriopsis cumingii; (2) taking the margin tissues of the pallium of the parent hyriopsis cumingii, extracting the total RNA (ribonucleic acid) and synthetic single stranded c RNA, performing SRAP (sequence-related amplified polymorphism) amplification by adopting primer combination, and selecting male and female individuals with specific strip sequences with the golden yellow shells after the amplification products are subjected to electrophoresis; (3) using the selected male and female parent hyriopsis cumingii to build a family and cultivating in a water flowing pool; (4) periodically examining the pregnant condition of the female hyriopsis cumingii, and if mature glochidiums are found, selecting the mature female hyriopsis cumingii to reproduce to obtain infant hyriopsis cumingii; cultivating the infant hyriopsis cumingii in the water flowing pool until the shell reaches 1-2cm long, removing into to a net cage, and suspending the net cage into a pond to perform second stage cultivating on the infant hyriopsis cumingii until the shell length reaches 5-8cm; (5) removing the family parent hyriopsis cumingii with the non-golden yellow shells, and using the rest parent hyriopsis cumingii to build a core cultivating population with the golden yellow shells. According to the cultivation method of the hyriopsis cumingii with the golden yellow shell, the ratio of the hyriopsis cumingii with the golden yellow shell can reach more than 99.0%, the shell color is stable in heredity and the postoperative survival rate is high.

The invention relates to a bladder cancer pathomics intelligent diagnosis method based on machine learning and a prognosis model thereof, and the method is characterized in that the method comprises the following steps: S1, preforming data acquisition; S2, processing a microscopic pathology image; S3, performing bladder cancer pathological image feature extraction; S4, constructing and inspectinga bladder cancer automatic pathological diagnosis model based on machine learning; and S5, constructing and checking a bladder cancer survival prognosis prediction model based on machine learning. Thebladder cancer pathomics intelligent diagnosis method has the advantages that the bladder cancer pathomics intelligent diagnosis method is constructed based on pathological section microscopic imagemachine learning, effective automatic pathological diagnosis can be achieved, pathological diagnosis is expected to be further promoted to be developed to the efficient and accurate field, and the current situation that domestic pathology physicians are in shortage is relieved; the postoperative survival condition of the bladder cancer patient can be efficiently and accurately predicted, and important guidance opinions are provided for clinical decisions of clinicians.

The invention belongs to the technical field of biology and discloses application of a glioma prognostic marker Circ9:135881633|135883078, in particular to application of a reagent for detecting the expression quantity of cyclic RNA (Ribonucleic Acid) Circ9:135881633|135883078 from a brain tissue in preparing a prognostic preparation of a glioma patient. The study proves that patients with higherexpression quantity of the cyclic RNA Circ9:135881633|135883078 in the glioma have a higher postoperative survival rate. Prognostic judgement of the glioma patients is made by detecting the expressionlevel of the cyclic RNA Circ9:135881633|135883078 in glioma tissues of the glioma patients.

The invention belongs to the fields of genetic engineering and medical detection, and relates to a human colorectal carcinoma molecular marker COL3A1 and an application thereof in preparing a human colorectal carcinoma detecting preparation or a detecting kit. On the basis of an experiment of analyzing the expression of a COL3A1 gene in colorectal carcinoma and para-carcinoma tissues, a result shows that the COL3A1 gene has a more significant high-expression trend in the carcinoma tissues in comparison with that in the para-carcinoma tissues, proving that the COL3A1 plays a role in the occurrence and development of the colorectal carcinoma; the COL3A1 presents significant different expression in colorectal carcinoma and para-carcinoma epithelial cells but has no expression difference in carcinoma and para-carcinoma matrix parts, showing that the COL3A1 protein is the carcinoma epithelial cell specificity molecular marker; and meanwhile, up-regulation of the expression of the COL3A1 gene is positively related to tumor progression and is related to the postoperative survival time of a patient with the colorectal carcinoma. The invention provides a scientific basis for the effective judgment of canceration progression of the human colorectal carcinoma.

The invention discloses application of hsa_circ_0000284 in preparation of a neuroblastoma prognostic preparation, and relates to the technical field of molecular biology. The invention further discloses a nucleotide sequence of the hsa_circ_0000284, wherein the nucleotide sequence of the hsa_circ_0000284 is shown as SEQ ID NO:1, and the nucleotide sequences of the specific primers of the hsa_circ_0000284 are shown as SEQ ID NO:2 and SEQ ID NO:3. The survival curve analysis of 38 patients with neuroblastoma shows that the patients with high expression of hsa_circ_0000284 have a relatively poor postoperative survival rate (P is equal to 0.0107). According to the present invention, the expression level of the hsa_circ_0000284 is detected, such that the prognosis judgment is performed on the neuroblastoma patient so as to allow the hsa_circ_0000284 to be used as the important index of the clinical diagnosis evaluation of the neuroblastoma.

The invention provides a construction method of a model for predicting the survival rate of a patient with intrahepatic cholangiocarcinoma. The construction method comprises the following steps of 1)providing DNA methylation sequencing data of the intrahepatic cholangiocarcinoma; 2) analyzing the DNA methylation sequencing data, and screening out a plurality of related promoter regions of the intrahepatic cholangiocarcinoma; and 3) establishing a model for predicting the survival rate of the intrahepatic cholangiocarcinoma patient by utilizing the plurality of related promoter regions of theintrahepatic cholangiocarcinoma. By conducting DNA methylation prognostic labeling on intrahepatic cholangiocarcinoma patients, the DNA methylation markers serve as independent variables, the patientsare distinguished into a high death rate group and a low death risk group, and experimental verification shows that the construction method of the model can be used for predicting the total postoperative survival rate of the intrahepatic cholangiocarcinoma patients, and can be used for predicting the postoperative survival rate of the intrahepatic cholangiocarcinoma patients; an individualized adjuvant therapy strategy is provided for a patient with the intrahepatic cholangiocarcinoma.

The invention discloses a kit for predicting postoperative survival time of a lung squamous carcinoma patient and application of the kit, and relates to the technical field of gene engineering. The kit comprises a reagent for detecting a target region, wherein the target region is selected from a non-coding region of a WDR74 gene. It is found that the WDR74 gene is a drive gene of lung squamous carcinoma, and based on the detection result of the mutation of the non-coding region of the WDR74 gene, the survival time of the lung squamous carcinoma patient after an operation can be predicted, auxiliary information is provided for the diagnosis and/or treatment of the lung squamous carcinoma patient, and the survival rate of the lung squamous carcinoma patient is improved.

The invention belongs to the fields of molecular biology and clinical detection, and relates to application of a protein marker or a combination thereof in prognosis judgment of colorectal cancer. Specifically, the invention relates to use of any one item selected from following (1)-(7) items in preparation of medicines for diagnosis, assessment of recurrence risk, prognostic judgment or assistance therapy of colorectal cancer (such as colorectal cancer stage II or stage III), wherein the(1)-(7) items are (1) p-mTOR, (2) p-mTOR, MAP4, (3) p-mTOR, DNAJB6, (4) MAP4, (5) MAP4, DNAJB6, (6) p-mTOR,MAP4, DNAJB6 and (7) reagents, and any one item of the (1)-(6) items can be detected (such as quantitative detection or qualitative detection). The marker or the marker combination can be effectivelyused for judging the prognosis of patients with colorectal cancer, such as the prediction of postoperative survival time and median survival time of the patients.

The invention discloses an establishing method and application for a multi-gene liver cancer prognosis grading system. The system can be used to predict survival time and recurrence probability of patients with liver cancer after surgery, regardless of the ages and tumor sizes of the patients. Samples come from a total of 378 clinical liver cancer surgery patients in a hospital affiliated to Zhejiang University School of Medicine in 2012-2018, after strict quality control of the samples, through a multi-gene quantitative real time polymerase chain reaction (qRT-PCR), the correlation between each gene and the survival time is further analyzed, and finally high-risk genes related to prognosis of the clinical liver cancer surgery patients are screened to establish the prognosis grading system. The method has the following beneficial effects: the prognosis grading system capable of predicting the survival time and recurrence probability of the clinical liver cancer patients after the surgery is established, regardless of the ages and tumor sizes of the patients, and the system can be used for postoperative survival time assessment of the liver cancer surgery patients, and assist in formulation of a postoperative treatment plan for the patients.

The invention relates to the field of medical instruments, in particular to a bionic auxiliary system for postoperative recovery of stomach tumor patients. The bionic auxiliary system mainly comprises a deck chair adopting bionic design, and a chair back, arm supporting plates, armrests, a chair seat and leg supporting plates of the deck chair can be adjusted in a high-degree-of-freedom mode so as to meet the use requirements of a patient; a walking device is further arranged in cooperation with the deck chair, and the leg supporting plates with bionic joints are used in cooperation with the deck chair, so that the patient can walk while keeping a lying posture on a bionic recuperating chair, the requirement that the patient needs to move after a meal is met, and various common postoperative complications of the stomach tumor patient can be reduced at the same time; and in addition, a visual operation table used for relieving the mood of the patient and giving recovery and recuperation instructions is further arranged, the patient can be further helped to keep happy, correct recuperation guidance is given to the patient, the postoperative survival rate of the patient can be effectively increased, and the survival time of the patient can be effectively prolonged.